SEP 4199
Total Payments
$72,711
Transactions
59
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $72,711 | 59 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,711 | 59 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression | Sunovion Pharmaceuticals Inc. | $72,711 | 0 |
Top Doctors Receiving Payments for SEP 4199
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $72,711 | 59 |
Ad
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $72,711
Product Information
- Type Drug
- Total Payments $72,711
- Total Doctors 0
- Transactions 59
About SEP 4199
SEP 4199 is a drug associated with $72,711 in payments to 0 healthcare providers, recorded across 59 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2020 to 2020. In 2020, $72,711 was paid across 59 transactions to 0 doctors.
The most common payment nature for SEP 4199 is "Unspecified" ($72,711, 100.0% of total).
SEP 4199 is associated with 1 research study, including "A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression" ($72,711).